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Introduction
The gene encoding IL-26 was discovered in Herpesvirus saimiri–
transformed human T cells, with approximately 25% sequence 
homology and approximately 47% amino acid similarity to IL-10 
(1). As such, IL-26 is considered a member of the IL-10 cytokine 
family, which includes IL-10, IL-19, IL-20, IL-22, and IL-24 (2, 3). 
The IL26 gene is located on chromosome 12q15, between IFNG and 
IL22. IL26 is highly conserved in mammalian species and more 
weakly similar to nonmammalian species. However, IL26 is absent 
in rodents, despite the presence of both IL-26 receptor genes (4–6). 
IL-26 contains 171 amino acids, including lysine or arginine 30 
residues, forming 6 highly cationic α-helices (1). Th17 cells are the 
main producers of IL-26 (7, 8), but some Th1 cells (9) and NK cells 
(10) are reported to produce this cytokine. Although monocytes 
(11) and macrophages (12) have been reported to release IL-26, the 
purity of the cell populations was not clearly stated.
The structure of IL-26, including the α-helices, the amphipa-
thic stretches, the clustering of cationic charges, and the forma-
tion of multimers, are hallmarks of naturally occurring antimicro-
bial peptides (13, 14). This led to the discovery that IL-26 is the only 
known Th17 cytokine with antimicrobial properties, with the abil-
ity to kill extracellular bacteria including Pseudomonas aeruginosa, 
Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus 
that largely reside and replicate outside of cells (3, 9). Similar to 
other antimicrobial proteins, IL-26 reduced bacterial viability via 
direct binding to the bacterial cell wall, leading to pore formation 
and membrane disruption (9).
In addition to its direct antimicrobial activity, IL-26 was shown 
to signal through the IL-10R2/IL-20R1 heterodimeric receptor, with 
both subunits simultaneously expressed exclusively and constitu-
tively by epithelial cells (15, 16). Despite sharing homology with the 
antiinflammatory cytokine IL-10 and a receptor subunit with the 
IL-10 receptor, the majority of evidence indicates that IL-26 not only 
initiates inflammation but also propels it (17–19). IL-26 was found to 
induce the expression of IL-10, TNF-α, and IL-8 in epithelial cells, as 
well as inhibit their proliferation (20). IL-26 can also drive inflamma-
tion by acting as a potent chemoattractant for neutrophils (12), which 
subsequently can be activated to release inflammatory cytokines, 
proteases, and antimicrobial peptides (21). One report indicated 
that, although IL-26 by itself induced cytokine responses in broncho-
alveolar lavage (BAL) cells, it inhibited the release of myeloperoxi-
dase from BAL cells and neutrophils by less than 25% (12).
In the present study, we investigated whether IL-26 contrib-
utes to host defense against the obligate intracellular bacterium 
by studying human leprosy as a model. The disease, caused by 
the Mycobacterium leprae, forms a spectrum, in which the clini-
cal presentation correlates with the effectiveness of the immune 
response. In the self-limited tuberculoid leprosy (T-lep) form, 
the bacteria are eliminated, whereas, in the disseminated lepro-
matous (L-lep) form, bacilli-laden macrophages are prominent, 
indicating an inability to contain the infection. The results provide 
evidence that IL-26 may act intracellularly as well as extracellular-
ly to kill microbial pathogens.
IL-26 is an antimicrobial protein secreted by Th17 cells that has the ability to directly kill extracellular bacteria. To ascertain 
whether IL-26 contributes to host defense against intracellular bacteria, we studied leprosy, caused by the obligate 
intracellular pathogen Mycobacterium leprae, as a model. Analysis of leprosy skin lesions by gene expression profiling and 
immunohistology revealed that IL-26 was more strongly expressed in lesions from the self-limited tuberculoid compared 
with expression in progressive lepromatous patients. IL-26 directly bound to M. leprae in axenic culture and reduced bacteria 
viability. Furthermore, IL-26, when added to human monocyte–derived macrophages infected with M. leprae, entered 
the infected cell, colocalized with the bacterium, and reduced bacteria viability. In addition, IL-26 induced autophagy via 
the cytoplasmic DNA receptor stimulator of IFN genes (STING), as well as fusion of phagosomes containing bacilli with 
lysosomal compartments. Altogether, our data suggest that the Th17 cytokine IL-26 contributes to host defense against 
intracellular bacteria.
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expressing cells, as we could not determine whether IL-26 was 
being produced or taken up by individual cells. The IL-26 to nucle-
ar staining ratio was approximately 10-fold higher in T-lep lesions 
than in L-lep lesions: 56 ± 8.5 vs. 5.2 ± 3.0 (P < 0.05, Figure 1D).
We used confocal laser microscopy to determine the relative 
localization of IL-26 in relation to T cells and macrophages within 
leprosy lesions. Again, we observed that IL-26 expression was great-
er in T-lep lesions than in L-lep lesions, colocalizing more frequent-
ly with CD4+ T cells in T-lep versus L-lep lesions (Figure 2, A and B) 
and, to a lesser extent, with CD8+ T cells (Figure 2, C and D). The 
frequency of CD4+ T cells that colocalized with IL-26 was greater in 
T-lep lesions, at 26.7% ± 3.7% compared with 3.2% ± 0.7% in L-lep 
lesions (P < 0.01, Figure 2B). In addition, the frequency of CD8+ 
T cells that colocalized with IL-26 was greater in T-lep lesions, at 
17.5% ± 1.2%, compared with L-lep lesions, which had 7.2% ± 1.3% 
colocalization (P < 0.05, Figure 2D). In a simultaneous comparison 
of the levels of colocalization of IL-26 with the CD4+ and CD8+ T cell 
markers, we found that IL-26 colocalized significantly more with 
CD4+ than with CD8+ T cells (P < 0.05, Figure 2E). Additionally, we 
analyzed the relative location of IL-26 in relation to CD68+ macro-
phages in leprosy lesions and found that IL-26 was coexpressed with 
CD68 in both types of lesions (Figure 3A). However, the degree of 
colocalization between IL-26 and the CD68 marker was also high-
er in T-lep lesions than in L-lep lesions (16.8% ± 2.1% versus 8.3% 
± 1.1%, respectively) (P < 0.05, Figure 3B). We also observed areas 
in T-lep granulomas in which IL-26 colocalized with both CD4+ 
and CD68+ cells (Figure 3C). In a simultaneous comparison of the 
Results
IL-26 expression in human leprosy. We mined the gene expression 
data derived from leprosy lesions (22) to determine whether there 
was differential expression of IL26 mRNA across the spectrum of 
disease. This analysis revealed that IL26 mRNA levels were sig-
nificantly greater in the skin biopsy specimens from T-lep patients 
compared with those from L-lep patients (Figure 1A), with probe 
intensities of 408 ± 118 in the gene expression data from T-lep 
lesions versus 33 ± 11 from L-lep lesions (P < 0.05). In 7 of 10 spec-
imens from T-lep donors, the expression of IL26 mRNA was great-
er than in the specimens from all the L-lep donors.
We further assessed the differences in IL-26 expression in lep-
rosy lesions by immunohistochemical analysis with an anti–IL-26 
monoclonal Ab. IL-26 protein expression was abundant in T-lep 
lesions, throughout the granuloma, and particularly strong in the 
vicinity of small lymphoid cells, but was also diffusely present 
near larger mononuclear myeloid cells (Figure 1B). In contrast, 
IL-26 expression was sparse throughout the L-lep lesions. We also 
assessed the specificity of the anti–IL-26 mAb by adding recombi-
nant monomers of IL-26 protein to the Ab prior to tissue staining. 
Saturation of the mAb by recombinant IL-26 reduced the signal 
intensity in T-lep lesions, demonstrating specificity of the Ab to the 
protein (Figure 1C). Anti-CD3 served as a positive control. All iso-
type controls were consistently negative. Quantification was per-
formed using the online software ImmunoRatio (23) to measure 
the IL-26 to nuclear staining ratio, which provides a measure of 
IL-26 expression. This ratio is not intended as a measure of IL-26–
Figure 1. IL-26 in leprosy lesions. (A) IL26 mRNA 
probe intensity of skin leprosy lesions was quan-
tified by microarray gene expression. **P < 0.01, 
by Student’s t test. (B) IL-26 expression in leprosy 
lesions (T-lep and L-lep). Shown are 2 representa-
tive labeled sections from at least 4 individuals. 
Scale bars: 40 μm. (C) IL-26 expression following 
saturation of IL-26 Ab with rIL-26, demonstrating 
Ab specificity. Shown is 1 representative labeled 
section from 1 of 3 individuals. Scale bars: 20 μm. 
(D) Ratio of IL-26 and nuclear staining quantified by 
ImmunoRatio. Data represent the mean ± SEM (n = 
4). *P < 0.05, by 2-tailed Student’s t test.
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microanatomic location of IL-26 but cannot distinguish between 
production versus uptake of the protein.
IL-26 directly reduces the viability of mycobacteria in axenic con-
ditions. As a first step toward defining the role of IL-26 against 
levels of colocalization of IL-26 with the CD4 and CD68 markers, 
we found that IL-26 colocalized significantly more with CD4+ than 
with CD68+ (P < 0.05, Figure 3D). These data show the proximity 
of IL-26 to CD4+ and CD68+ cells, but again, these data define the 
Figure 2. IL-26 colocalization 
with CD4 and CD8. (A) Immu-
nofluorescence of IL-26 (green), 
CD4 (red), and nuclei (DAPI, blue) 
in T-lep and L-lep lesions. Data 
are representative of 4 individual 
samples. Original magnification, 
×20. Scale bars: 10 μm (enlarged 
insets). (B) Colocalization of 
CD4 and IL-26, as determined 
by ImageJ. Data represent the 
mean ± SEM (n = 4). **P < 0.01, 
by 2-tailed Student’s t test. (C) 
Immunofluorescence of IL-26 
(green), CD8 (red), and nuclei 
(DAPI, blue) in T-lep and L-lep 
lesions. White arrows indicate 
colocalization of green and red 
(yielding yellow). Original magni-
fication, ×20. Scale bars: 10 μm 
(enlarged insets). (D) Colocaliza-
tion of CD8 and IL-26, as deter-
mined by ImageJ. Data represent 
the mean ± SEM (n = 4). *P < 
0.05, by 2-tailed Student’s t test. 
(E) Comparison of CD4 or CD8 
colocalization with IL-26 in T-lep 
using ImageJ. Data represent the 
mean ± SEM (n = 4). *P < 0.05, 
by 2-tailed Student’s t test.
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treatment of M. leprae–infected MDMs with Alexa 488–labeled 
IL-26 revealed colocalization of intracellular bacilli with IL-26 
(Figure 6D). The degree of IL-26 colocalization with M. leprae was 
similar for treatment with the 1-μM and 2-μM concentrations of 
the cytokine: 11.9% ± 1.5% and 11% ± 0.6%, respectively (Figure 
6E). Finally, we assessed whether pretreatment of MDMs with 
IL-26 affects the levels of infectivity by M. leprae. Although pre-
treatment of MDMs with IL-26 slightly reduced the infection effi-
ciency of M. leprae, the differences in the percentages of M. leprae–
infected MDMs were not statistically significant (Figure 6F).
IL-26 induces autophagy and enhances bacterial trafficking to 
the lysosomes. The process of autophagy is required to overcome 
the ability of mycobacteria to block phagolysosomal fusion in 
infected macrophages in order to promote an effective antimi-
crobial response (28–30). Immunofluorescence data indicated a 
significant increase in the number of autophagosomes in MDMs 
following treatment with IL-26 compared with media control, as 
determined by quantification of LC3 puncta (Figure 7A). In media 
alone, we observed 8.3 ± 1.3 puncta per cell compared with IL-26 
treatment, in which 57.9 ± 5.5 puncta per cell were detected (P < 
0.01, Figure 7B). The ability of IL-26 to induce autophagy was con-
firmed by LC3 I to LC3 II conversion by immunoblotting (Figure 
7C). Given that IL-26 has been shown to bind to DNA from dying 
cells in in vitro cultures and traffic this DNA to activate innate 
cytoplasmic receptors, e.g., stimulator of IFN genes (STING) 
(9, 31), we investigated whether IL-26–induced autophagy was 
STING dependent. We found that IL-26 induced autophagy in WT 
THP-1 cells but was strikingly diminished in THP-1 cells in which 
STING was ablated by stable KO. In contrast, rapamycin-induced 
autophagy was STING independent (Figure 7D). Overall, IL-26–
induced autophagy in THP-1 cells, as measured by the number of 
LC3 puncta per cell, was blocked by approximately 60% by the 
deletion of STING (Figure 7E). In contrast, only 25% of rapamy-
cin-induced autophagy was STING dependent.
Having demonstrated that IL-26 induces autophagy and colo-
calizes with M. leprae bacilli during infection, we hypothesized 
that bacteria would localize to autophagosomes following IL-26 
stimulation. We observed a significant increase in colocalization 
of M. leprae with the autophagosome marker LC3 and the lyso-
some marker LAMP1 (Figure 7F). We observed 5.1% ± 0.7% colo-
calization between M. leprae and LC3 in the media control–treated 
MDMs versus 18.9% ± 1.4% and 26% ± 1.9% colocalization in 
the 1-μM and 2-μM IL-26–treated MDMs, respectively (P < 0.05, 
Figure 7G). We noted a similar increase in the colocalization of 
M. leprae and LAMP1 following IL-26 stimulation, with 1.3% ± 
0.2% colocalization between M. leprae and LAMP1 in the media 
control–treated MDMs versus 3.3% ± 0.4% and 6.4% ± 0.8% colo-
calization in the 1-μM and 2-μM IL-26–treated MDMs, respec-
tively (P < 0.01, Figure 7H). Although treatment with the higher 
concentration of IL-26 induced more M. leprae colocalization 
with LAMP1, we observed that IL-26 colocalization with LAMP1 
remained comparable following treatment with either 1 μM or 2 
μM IL-26 (Figure 7, I and J), consistent with our observations with 
uninfected MDMs (Figure 6C). This suggests that the mechanism 
driving the increased traffic of M. leprae to LAMP1 compartments 
in infected MDMs is not through increased expression of LAMP1 
but potentially through IL-26–induced autophagy.
intracellular M. leprae, we determined whether IL-26 bound to 
the bacterium. M. leprae was incubated with recombinant IL-26 
protein in axenic culture. After 6 hours, IL-26 was detected on the 
surface of some M. leprae bacilli (Figure 4, A and C). Quantifica-
tion of confocal images confirmed that the majority of bacilli were 
bound by IL-26, 89.5% ± 0.5%, leaving 9.5% ± 0.51.1% free bacil-
li (Figure 4B). Analysis of confocal images using Imaris software 
revealed that the bacilli that were bound to IL-26 were larger in 
diameter, as measured by transverse width, compared with media 
controls. The width of the bacilli increased from 0.359 ± 0.012 μm 
in media-treated bacteria to 0.528 ± 0.023 μm in 1 μM or 0.591 ± 
0.038 μm in 2 μM of IL-26–treated bacteria (P < 0.01, Figure 4D). 
The increased diameter is consistent with osmotic lysis of the bac-
teria, one mechanism by which antimicrobial peptides mediate an 
antimicrobial response.
Although M. leprae does not grow in culture, it is possible to 
measure bacterial viability by quantitative PCR (qPCR) using the 
ratio of M. leprae 16S rRNA to the repetitive element DNA RLEP 
as a proxy for transcriptional activity, as previously reported (22, 
24, 25). We studied the effects of IL-26 in axenic culture to deter-
mine whether it further reduced bacterial viability and found that 
IL-26 treatment of M. leprae for 3 days reduced the viability of the 
bacteria in a dose-dependent manner (Figure 5A). The observed 
antimicrobial activity was diminished when IL-26 was denatured 
prior to addition to M. leprae (Figure 5B). Similarly, IL-26 inhibited 
the growth of Mycobacterium tuberculosis H37Ra in axenic culture, 
quantified by a CFU assay (Figure 5C). These findings reveal that 
IL-26 binds directly to mycobacteria and mediates a reduction in 
bacteria viability.
IL-26 is taken up by monocyte-derived macrophages and colocal-
izes with M. leprae. During M. leprae infection, bacilli can be found 
in a variety of tissues and cell types but are predominantly located 
in macrophages (26, 27). Although it has been reported that IL-26 
concentrations up to 10 μM did not affect the viability of human 
primary human immune cells (9), we specifically assessed the 
cytotoxic effects of IL-26 on human monocyte–derived macro-
phages (MDMs). When we treated MDMs with increasing con-
centrations of IL-26, we observed some detachment of MDMs 
from the culture plates with the 2-μM IL-26 treatment. With 5-μM 
IL-26 treatment, the majority of cells were detached, and the cells 
that remained showed condensed nuclei and positive staining by 
TUNEL assay, indicative of cellular apoptosis (Figure 6A). There-
fore, we stimulated MDMs with IL-26 at 2 μM or less in all remain-
ing experiments to ensure optimal cell viability.
Because M. leprae is an obligate intracellular organism, IL-26 
must gain access to the intracellular compartments in which the 
bacteria reside in order to exert a direct antimicrobial activity. 
We therefore evaluated whether IL-26 entered MDMs and could 
be detected in the endosomal pathway in which M. leprae resides. 
Overnight treatment of MDMs with Alexa 488–labeled IL-26 
resulted in the uptake of IL-26 and colocalization with lysosom-
al-associated membrane protein 1–positive (LAMP1-positive) 
compartments (Figure 6B). The colocalization of Alexa 488–
labeled IL-26 with LAMP1 was significantly greater than was seen 
with the addition of Alexa 488 dye alone, increasing from 2.3% ± 
0.4% colocalization in dye media alone to 19.6% ± 3.3% in 1 μM 
and 23% ± 2.3% in 2 μM IL-26 (P < 0.01, Figure 6C). Furthermore, 
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Figure 3. IL-26 colocalization with CD68+ macrophages in 
leprosy lesions. (A) Immunofluorescence of IL-26 (green), 
CD68 (red), and nuclei (DAPI, blue) in T-lep and L-lep 
lesions. White arrows indicate colocalization of IL-26 and 
CD68. Data are from 5 individual samples. Original mag-
nification, ×20. Scale bars: 10 μm (enlarged insets). (B) 
Colocalization of IL-26 and CD68 in T-lep and L-lep lesions 
using ImageJ. Data represent the mean ± SEM (n = 5). *P 
< 0.05, by 2-tailed Student’s t test. (C) Immunofluores-
cence of IL-26 (green), CD68 (red), CD4 (cyan), and nuclei 
(DAPI, blue) in T-lep and L-lep lesions. Data are from 3 
individual samples. White arrows indicate colocalization 
of IL-26 (green) and CD68 (red) (yielding yellow). Original 
magnification, ×20. Scale bars: 10 μm (enlarged insets). 
(D) Comparison of CD4 or CD68 colocalization with IL-26 
in T-lep using ImageJ. Data represent the mean ± SEM  
(n = 4). *P < 0.05, by 2-tailed Student’s t test.
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IL-26 induces antimicrobial activity against intracellular bac-
teria. Finally, we sought to determine whether IL-26 treatment 
during infection would result in antimicrobial activity against M. 
leprae. Indeed, we found that IL-26 treatment during M. leprae 
infection significantly reduced the viability of intracellular bac-
teria compared with media control. The addition of 2 μM IL-26 
to the infected MDMs was required to reduce the viability of the 
intracellular bacteria by approximately 40%, much less than the 
10-μM amount needed to have similar effects in axenic culture (P 
< 0.05, Figure 8A). Antimicrobial activity was dependent on the 
native structure of IL-26, because denaturing the protein did not 
produce the same results (P < 0.05, Figure 8B). We observed simi-
lar antimicrobial activity against M. tuberculosis (H37Ra) in MDMs 
(P < 0.05, Figure 8C). We note that in one study, the addition of 
IL-26 to M. tuberculosis–infected whole blood, albeit at lower con-
centrations (~700-fold lower than given here), did not result in 
an antimicrobial response; however, the authors stated that the 
nature of the whole-blood antimicrobial assay made interpreta-
tion of this result difficult (11).
To further investigate the ability of IL-26 to mediate an anti-
microbial response against intracellular bacteria, we infected 
MDMs with Staphylococcus aureus, which, when taken up by 
macrophages, has been reported to inhibit autophagy and acidi-
fication of phagolysosomes (32–34). Compared with the media 
control, we observed that IL-26 treatment of MDMs significant-
ly reduced the viability of intracellular S. aureus (P < 0.05, Figure 
8D). Having demonstrated that IL-26 can induce autophagy in 
MDMs, we sought to determine whether autophagy is required 
for antimicrobial activity. We used the PI3K inhibitor wortman-
nin to block IL-26–induced autophagy. The addition of wortman-
nin prior to IL-26 stimulation significantly reduced antimicrobial 
activity, which we observed by the increased viability of M. leprae, 
from 53% ± 7.8% with 2 M IL-26 treatment to 86.7% ± 10.1% with 
wortmannin (P < 0.05, Figure 8E). In summary, these data demon-
strate that IL-26 treatment of infected MDMs leads to autophagy, 
colocalization of IL-26 with the bacilli in LAMP1 compartments, 
and an antimicrobial response against intracellular bacteria.
Discussion
The adaptive T cell response kills intracellular pathogens through 
direct and indirect mechanisms. For example, CD8+ cytotoxic T 
cells deliver cytotoxic granule contents including the antimicro-
Figure 4. IL-26 binds directly to M. leprae bacilli. (A and C) Confocal microscopic images of Alexa 488–IL-26 (green) cultured with M. leprae (red) for 6 
hours. Data shown are representative of 4 independent experiments. Scale bars: 5 μm. (B) Quantification of number of free bacilli or IL-26–bound bacilli 
(left) and percentage of free or IL-26–bound bacilli of total bacilli counts (right). (D) Measurement of M. leprae bacilli thickness from the confocal micros-
copy images in C. Media contained Alexa Fluor 488 dye as a control. Data represent the mean ± SEM (n = 50 bacilli for each condition). Data shown are 
representative of 4 independent experiments. ***P < 0.001, by repeated-measures 1-way ANOVA.
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bial protein granulysin into infected macrophages, leading to a 
direct reduction in the viability of intracellular pathogens (35–38). 
CD4+ Th1 cells release IFN-γ, which triggers an indirect antimi-
crobial mechanism through activation of endogenous pathways 
in macrophage microbicidal pathways. Given that CD4+ Th17 
cell production of IL-26 provides a direct antimicrobial pathway 
against extracellular bacteria (9), we explored whether IL-26 can 
mediate an antimicrobial response against intracellular bacteria. 
We provide evidence that IL-26 enters bacteria-infected macro-
phages, induces autophagy, and colocalizes with the pathogen, 
together resulting in an antimicrobial response. These data iden-
tify a role for IL-26 in host defense against intracellular bacteria.
We examined the role of IL-26 in leprosy, which provides 
a unique model, given that the disease presents as a spectrum 
in which the clinical presentation correlates with the immune 
response to the pathogen. Measuring mRNA and protein levels at 
the site of disease, we observed that IL-26 expression was greater 
in lesions from patients with T-lep than in those with L-lep, cor-
relating with the group of patients with the greatest cell-mediated 
immunity against the pathogen. IL-26 colocalized with T cells but 
also with CD68+ macrophages, indicating proximity to the cell type 
infected by the leprosy bacillus. The colocalization of IL-26 with 
CD68+ macrophages was significantly (P < 0.05) greater in T-lep 
than L-lep lesions, even though there are comparable numbers 
of macrophages in the different forms of leprosy (38). The higher 
expression levels of IL-26 in T-lep lesions correlate with the lower 
bacterial load in this form of leprosy (39, 40). In contrast, the rela-
tively lower expression of IL-26 that we observed in L-lep lesions is 
associated with a higher bacterial load in this form of leprosy. The 
lack of IL-26 may permit bacterial growth, and/or the bacilli may 
potentially inhibit the production and secretion of IL-26. For exam-
ple, expression of IL-4, IL-10, and type I IFN has been reported to 
be higher in L-lep compared with T-lep lesions, and these cyto-
kines are known to inhibit antimycobacterial pathways (22, 41–44). 
Accordingly, the type I IFN gene expression profile is also enhanced 
in the blood of patients with active tuberculosis (45, 46), which may 
contribute to the lower amount of IL-26 release following M. tuber-
culosis infection of a monocyte-enriched population from patients 
with tuberculosis compared with healthy controls (11).
IL-26 may contribute to an antimicrobial response against 
intracellular bacteria in infected macrophages through 2 mecha-
nisms. First, IL-26 had direct antimicrobial activity against intra-
cellular mycobacteria, as shown in axenic culture, and colocalized 
with M. leprae in infected MDMs. Second, we found that IL-26 
induces autophagy in MDMs, which was required for its antimi-
crobial response against intracellular M. leprae. Since mycobac-
teria are known to inhibit the phagolysosomal fusion required for 
intracellular killing (47), and S. aureus is known to subvert acid-
ification of phagolysosomes (32–34), IL-26 may stimulate infect-
ed cells to overcome this inhibition, facilitating the antimicrobial 
response. Additionally, the higher expression of IL-26 we detected 
in T-lep lesions also correlates with the higher number of autopha-
gosomes detected in this form of leprosy (48). Although autophagy 
is required for killing of intracellular mycobacteria, some intracel-
lular bacteria evade autophagy-dependent killing (28–30).
We found that IL-26–induced autophagy was dependent on 
the cytoplasmic DNA receptor STING, consistent with the demon-
strated ability of IL-26 to bind to DNA from dying cells in in vitro 
cultures and traffic this DNA to activate STING (9, 31), and the 
ability of STING activation to trigger autophagy in mycobacteria- 
infected macrophages (49). Although the IL-26 receptor, a het-
erodimer composed of IL-10R2 and IL-20R1, is expressed exclu-
sively and constitutively by epithelial cells (15, 16), human mono-
cytes and macrophages express IL-10R2 but not IL-20R1. One 
report demonstrated that IL-26 induction of IL-6 from monocytes 
was blocked by approximately 50% using a polyclonal goat anti–
IL-10R2 Ab, thereby triggering IL-10R2 alone or in combination 
with an undetermined coreceptor (19). It is therefore possible that 
IL-10R2 in myeloid cells is involved in uptake and/or signaling of 
IL-26 to induce autophagy.
Given that IL-26 is produced by Th17 cells, our data, along 
with previous studies, suggest the possibility that Th17 cells con-
Figure 5. IL-26 has direct antimicrobial activity against mycobacteria. (A) M. leprae was cultured for 4 days with increasing concentrations of IL-26. 
Rifampicin (Rif) was used as a positive control. Viability of M. leprae was calculated by the ratio of bacterial 16S rRNA and RLEP DNA detected by qPCR. 
Relative viability was determined by comparing the treatment ratio with the media ratio. Data represent the mean ± SEM (n = 5). (B) M. leprae (mLEP) 
was cultured for 4 days with 10 μM native IL-26 or denatured IL-26 (dIL-26). Rifampicin was used as a positive control. Viability of M. leprae was calculated 
according to the ratio of bacterial 16S rRNA and RLEP DNA detected by qPCR. Relative viability was determined by comparing the treatment ratio with 
the media ratio. Data represent the mean ± SEM (n = 5). (C) M. tuberculosis (mTB H37Ra) was cultured for 4 days with increasing concentrations of IL-26. 
Rifampicin was used as a positive control. A CFU assay was performed and numbers quantified after 3 weeks. Data represent the mean ± SEM (n = 5).  
*P < 0.05 and **P < 0.01, by repeated-measures 1-way ANOVA.
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sy susceptibility (52). The related bacterium M. tuberculosis induc-
es IL-23, a key cytokine in Th17 polarization by DCs (53), as well as 
Th17 cells (54). Yet, IL-17R–/– (55) and IL-23–/– (54) mice were more 
susceptible to M. tuberculosis infection. In mouse models of tuber-
culosis, IL-17 was required for the generation of IFN-γ–producing 
tribute to host defense in leprosy. Serum IL-17 was lowest in L-lep 
patients compared with serum levels in all other forms of lepro-
sy (50). Th17 cells were more frequent in both the lesions and M. 
leprae–stimulated PBMCs in patients with T-lep versus those with 
L-lep (51). Furthermore, SNPs in IL17F were associated with lepro-
Figure 6. IL-26 is taken up by MDMs and colocalizes with M. leprae. (A) Human MDMs were treated with IL-26 overnight. Cells were washed and fixed, and 
apoptosis was determined using a TUNEL (green) assay. Nuclei were stained with DAPI (blue). Data shown are from 5 individual donors. Scale bars: 5 μm. 
(B) Human MDMs were treated with Alexa 488–IL-26 (green) overnight. Cells were washed, fixed, and immunolabeled with anti-LAMP1 Ab (red). Nuclei 
were stained with DAPI (blue). Data shown are representative of 5 individual donors. Scale bars: 5 μm. Bottom row magnification, ×630. (C) Colocalization 
of LAMP1 (red) and IL-26 (green) was quantified with ImageJ. Data represent the mean percentage of colocalization ± SEM (n ≥ 50 cells from 3 donors). 
**P < 0.01, by repeated-measures 1-way ANOVA. (D) Human MDMs were treated with Alexa 488–IL-26 (green) for 30 minutes and infected with M. leprae 
(red) overnight. Cells were washed and fixed. Nuclei were stained with DAPI (blue). Media contained Alexa Fluor 488 dye as a control. Data shown are from 
4 individual donors. Scale bars: 5 μm. Bottom row magnification, ×630. (E) Colocalization of M. leprae (red) and IL-26 (green) was quantified with ImageJ. 
Data represent the mean percentage of colocalization ± SEM (n ≥ 40 cells from 4 donors). (F) Quantification of M. leprae–infected MDMs following 30 
minutes of treatment with IL-26. Data represent the mean percentage ± SEM (n = 4).
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Human U133 Plus 2.0 microarrays, were mined to assess IL26 mRNA 
expression (22, 62). The gene expression files containing these array 
data are available in the NCBI’s Gene Expression Omnibus (GEO) 
database (GEO GSE17763).
Generation of MDMs. MDMs were derived from whole blood from 
healthy donors. PBMCs were isolated using Ficoll (GE Healthcare) 
gradient centrifugation. CD14+ cells were positively selected from 
PBMCs using CD14 MicroBeads (Miltenyi Biotec, 130-050-201) 
and cultured in the presence of macrophage colony-stimulating fac-
tor (M-CSF) (50 ng/ml) (R&D Systems) and used on day 5 or 6. We 
routinely achieved a greater than 90% purity of monocytes by CD14 
immunomagnetic selection.
Viability of M. leprae by qPCR.  Cells were stimulated with various 
concentrations of IL-26 for 30 minutes and then infected with M. leprae. For 
autophagy inhibition, MDMs were treated with 500 nM wortmannin prior 
to IL-26 stimulation. mRNA was isolated from cells using TRIzol Reagent 
(Invitrogen Life Technologies, Thermo Fisher Scientific) according to the 
manufacturer’s recommended protocol. The viability of intracellular M. 
leprae was determined by qPCR and quantified as previously described 
(19, 22, 23). Briefly, comparison of the bacterial DNA with the mammali-
an 36B4 levels was used to monitor infectivity between all the conditions 
in the assay as well as PCR quality. The 16S rRNA and genomic DNA val-
ues were calculated using the ΔΔCt analysis, with the bacterial DNA value 
serving as the housekeeping gene. The primer sequences were as follows: 
M. leprae 16s RNA, forward, 5′-GCATGTCTTGTGGTGGAAAGC-3′; M. 
leprae 16s RNA, reverse, 5′-CACCCCACCAACAAGCTGAT-3′; M. leprae 
RLEP DNA, forward, 5′-GCAGCAGTATCGTGTTAGTGAA-3′; M. leprae 
RLEP DNA, reverse, 5′-CGCTAGAAGGTTGCCGTAT-3′; H36B4, for-
ward, 5′-CCACGCTGCT GAACATGCT-3′; H36B4, reverse, 5′-TCGAA-
CACCTGCTGGATGAC-3′.
M. tuberculosis axenic cultures. Recombinant IL-26 monomers 
(R&D Systems) were diluted in 10 mM sodium phosphate, pH 7.2. Ali-
quots of 2.5 × 105 M. tuberculosis (H37Ra) bacteria were added to 100 
μl Middlebrook 7H9 medium (BD Biosciences) containing recombi-
nant IL-26 monomers (R&D Systems) or 20 μg/ml (final concentra-
tion) rifampicin (Sigma-Aldrich). Cultures were incubated at 37°C for 
72 hours, after which 900 μl of 10 mM sodium phosphate, pH 7.2, was 
added to attain a volume of 1 ml. From the 1-ml suspension, 10 μl was 
plated onto Middlebrook 7H10 agar plates (Teknova) for 3 weeks, and 
CFU were enumerated.
Infection of MDMs and quantification of M. tuberculosis CFU. 
Human MDMs were pretreated with IL-26 (R&D Systems) or 1 μg/ml 
(final concentration) rifampicin (Sigma-Aldrich) in 10% Omega FCS 
for 30 minutes and infected with M. tuberculosis (H37Ra) at a MOI of 
5. The infected cells were harvested after 4 days, pelleted, and lysed 
with 100 μl of 0.2% saponin in 1× PBS on ice for 20 minutes. PBS 1× 
(900 μl) was added to bring the cell lysate to a 1-ml final volume. From 
the 1-ml suspension, 1 μl stock was plated onto Middlebrook 7H10 agar 
plates (Teknova) for 3 weeks, and CFU were enumerated.
IL-26 culture with M. leprae. Recombinant IL-26 monomers (R&D 
Systems) were diluted in 10 mM sodium phosphate, pH 7.2, and labeled 
using the Alexa Fluor 488 Microscale Protein Labeling Kit (Molecu-
lar Probes, Invitrogen, Thermo Fisher Scientific). Aliquots of 1 × 106 
M. leprae bacteria, labeled by PKH-26, were incubated with A488-
IL-26 in a 50-μl volume of 10 mM sodium phosphate, pH 7.2, for 6 
hours and then mounted onto microscopy slides with ProLong Gold 
(Invitrogen Life Technologies, Thermo Fisher Scientific). Images were 
Th1 cells (56), granuloma formation, inflammation (54, 56), and 
vaccine-induced immunity (57). However, the functional studies 
of Th17 cells in tuberculosis have utilized mouse models, and, as 
mentioned, IL-26 is not present in the mouse genome, such that 
it will be important to determine whether Th17 cells contribute to 
host defense through mechanisms other than IL-26 release.
In addition to mycobacteria, our data indicate that IL-26 has 
an antimicrobial effect on another cutaneous pathogen, S. aureus, 
when taken up by macrophages. Previous studies reported that 
defective Th17 responses in STAT3-deficient patients have been 
associated with increased susceptibility to S. aureus and Strep-
tococcus pyogenes infections (58, 59), potentially due to reduced 
STAT3 activation by IL-26 (60).
The current immunologic premise holds that Th1 cells defend 
against intracellular pathogens, whereas Th17 cells are required 
to defend against extracellular bacteria. In previous work, we 
demonstrated that Th1 cell release of IFN-γ activates macrophages 
to kill intracellular mycobacteria (22, 30), while human Th17 cells 
release IL-26, which kills extracellular bacteria in axenic (i.e., cell-
free) cultures (9). Nevertheless, vaccines that induce only Th1 
cells are not sufficient to engender protection against intracellular 
mycobacteria (61). Our data provide evidence that the Th17 cyto-
kine IL-26 can contribute to host defense against intracellular bac-
teria, identifying one mechanism by which Th17 cells contribute to 
host defense against such pathogens.
Methods
Microarray data analysis. The reported gene expression profiles of 
mRNAs derived from skin biopsy specimens from 16 patients with 
leprosy (T-lep, n = 10; L-lep, n = 6), as determined using Affymetrix 
Figure 7. IL-26 induces autophagy and enhances bacterial trafficking to 
the lysosomes. (A) MDMs were cultured with IL-26 or media overnight and 
then immunolabeled with anti-LC3 Ab (green) and anti-CD68 Ab (red). 
Nuclei were stained with DAPI (blue). Original magnification, ×63. Scale 
bars: 5 μm. (B) LC3 puncta per cell ± SEM (n ≥ 50 cells from 4 donors). (C) 
LC3 I to LC3 II conversion was detected by immunoblotting. Hsp90 was 
used as an internal control. (D) PMA-treated THP-1 cells were treated with 
IL-26 (2 μM) for 24 hours and with rapamycin (300 nM) for 6 hours and 
then immunolabeled with LC3 Ab (green). Nuclei were stained with DAPI 
(blue). Data shown are representative of 1 of 3 independent experiments 
for both WT and STING–/– THP-1 cells. Original magnification, ×63. (E) LC3 
puncta per cell ± SEM (n ≥ 50 cells from 3 donors for both WT and STING–/– 
THP-1 cells). (F) Human MDMs were treated with IL-26 for 30 minutes 
and infected with M. leprae (red) overnight. Cells were washed, fixed, and 
immunolabeled with anti-LC3 (green) and LAMP-1 (cyan). Nuclei were 
stained with DAPI (blue). Data shown are representative of 4 individual 
donors. Inset image is of LC3 (green) and M. leprae (red) overlay, without 
LAMP1 (cyan). Original magnification, ×63 and x630 (enlarged insets). (G) 
Colocalization of LC3 and M. leprae and (H) colocalization of LAMP1 and M. 
leprae were quantified with ImageJ. Data represent the mean percentage 
of the cellular volume of colocalization ± SEM (n ≥ 30 cells from 4 donors). 
(I) Human MDMs were treated with Alexa 488–IL-26 (green) for 30 minutes 
and infected with M. leprae (red) overnight. Cells were washed and immu-
nolabeled with anti-LAMP1 (cyan). Nuclei were stained with DAPI (blue). 
Media contained Alexa Fluor 488 dye as a control. Data shown are from 4 
individual donors. Scale bars: 5 μm. (J) Colocalization of IL-26 and LAMP1 
was quantified with ImageJ. Data are represented as the mean percentage 
of the cellular volume of colocalization ± SEM (n ≥ 40 cells from 4 donors). 
*P < 0.05 and **P < 0.01, by repeated-measures 1-way ANOVA.
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with 10% FCS antibiotic-free media. Next, 100 μg/ml gentamycin 
was added to the wells for 20 minutes to kill extracellular bacteria. 
Cells were then washed to further remove any remaining extracellular 
bacteria. Infected cells were cultured overnight at 37°C in a 4% CO2 
incubator. To measure intracellular killing of bacteria, cells were pel-
leted and lysed with 100 μl of 0.2% saponin in 1× PBS on ice for 20 
minutes. Next, 1× PBS (900 μl) was added to bring the cell lysate to 
a final volume of 1 ml, of which 1 μl was plated and CFU determined.
Patients and clinical specimens. Patients with leprosy were classi-
fied according to the criteria established by Ridley and Jopling (66). 
The designation of T-lep included patients who were classified clin-
ically as borderline tuberculoid (“BT”), and the designation of L-lep 
only included patients classified as “LL.” All T-lep and L-lep skin biop-
sy specimens were taken at the time of diagnosis, prior to the initiation 
of treatment. Specimens were embedded in OCT medium (Ames), 
snap-frozen in liquid nitrogen, and stored at –80°C.
Tissue immunoperoxidase labeling. Frozen tissue sections were 
blocked with normal horse serum before incubation 2 hours with 
mAbs against IL-26 (clone 2A8, IgG2a, Sigma-Aldrich) and CD3 (clone 
UCHT1, IgG1k, BD Biosciences), followed by incubation with bioti-
nylated horse anti–mouse IgG for 90 minutes. To test Ab specificity, 
IL-26 Ab was incubated with IL-26 monomers (R&D Systems) for 15 
minutes prior to incubation on tissue sections. Slides were counter-
stained with hematoxylin and mounted in crystal mounting medium 
(Biomeda) and were visualized using the ABC Elite system (Vector 
Laboratories). Skin sections were examined with a Leica microscope. 
Ratios were calculated using ImmunoRatio online software (Jorma 
Isola and Vilppu Tuominen, Institute of Biomedical Technology, Uni-
versity of Tampere, Tampere, Finland) (23), an automated image anal-
ysis application that calculates the percentage of DAB-stained nuclear 
area per total area.
Cell culture immunofluorescence labeling. Recombinant IL-26 
monomers (R&D Systems) were labeled using the Alexa Fluor 488 
examined using a Leica microscope. M. leprae bacilli diameters were 
measured using Imaris software.
Infection of MDMs and quantification of M. leprae viability. M. lep-
rae bacteria were grown in the footpads of nu/nu mice as described 
previously (63) and were provided by the National Hansen’s Disease 
Program. Human MDMs were pretreated with IL-26 (R&D Systems) 
in 10% Omega FCS for 30 minutes and infected with M. leprae at a 
MOI of 5. The infected cells were harvested after 4 days. RNA and 
DNA were isolated from infected cells using TRIzol (Invitrogen, Life 
Technologies, Thermo Fisher Scientific). cDNA was made from RNA. 
DNA was treated with RNase to removed residual RNA. The viability 
of intracellular M. leprae was determined by qPCR and quantified as 
previously described (22, 24). Briefly, the levels of bacterial 16S rRNA 
and the genomic DNA element RLEP of M. leprae were measured by 
qPCR. The 16S rRNA and RLEP DNA values were determined by 
ΔΔCt analysis, with the DNA value serving as the housekeeping gene. 
The ratio of RNA to DNA was calculated for each replicate, and the 
percentage of bacterial viability was calculated relative to the respec-
tive media control. The efficiency of infection was determined by con-
focal microscopy. Approximately 5% to 70% of the cells were infected. 
Of the total number of cells, more than 95% were viable following the 
washes and infection. To denature recombinant IL-26, the protein was 
treated with 5% β-mercaptoethanol (Invitrogen, Thermo Fisher Scien-
tific) and heated at 95°C for 10 minutes.
Infection of MDMs and quantification of intracellular S. aureus CFU. 
Bacteria of the S. aureus strain DU5938 (Hla−Hlb−Hlg−) (64) were 
grown to the mid-log phase at 37°C with shaking (150 rpm) in brain-
heart infusion (BHI) medium and then collected by centrifugation for 
10 minutes at 5000 g. For cellular infection, the bacterial suspension 
was diluted with sterile 1× PBS. The number of viable bacteria was 
determined by serial dilution and plating onto BHI agar plates (65). 
Human MDMs (2 × 106 cells) were pretreated with IL-26 for 4 hours, 
washed, and infected with S. aureus at an MOI of 5 for 4 hours in RPMI 
Figure 8. IL-26 induces antimicrobial activity against intracellular bacteria. (A) MDMs 
were treated with IL-26 for 30 minutes and then infected with M. leprae for 4 days. 
Rifampicin was used as a positive control. Viability of M. leprae was measured by 
qPCR (n = 6). (B) MDMs were treated with IL-26 or denatured IL-26 and then infected 
with M. leprae, and bacterial viability was measured as in A (n = 4). (C) MDMs were 
treated with IL-26 or denatured IL-26 and then infected with M. tuberculosis (H37Ra) 
as in A. Viability of intracellular M. tuberculosis was determined by CFU assay (n = 3). 
(D) MDMs were treated with IL-26 for 4 hours and then washed and infected with S. 
aureus for 4 hours, followed by removal of the extracellular bacteria. After overnight 
culture, the viability of intracellular S. aureus was determined by CFU assay (n = 5). (E) 
MDMs were treated with IL-26 with or without wortmannin (Wm) and then infected 
with M. leprae, and bacterial viability was measured as in A (n = 6). *P < 0.05 and **P 
< 0.01, by repeated-measures 1-way ANOVA. All data represent the mean ± SEM.
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ifornia NanoSystems Institute, UCLA). Colocalization quantifications 
were performed using ImageJ software.
Immunofluorescence colocalization analysis. The colocalization 
threshold plugin by ImageJ was used for all colocalization analyses 
related to confocal images. Briefly, this plugin compares 2 images for 
correlated pixel intensities, and a positive correlation between 2 imag-
es indicates that the signal in 1 channel (green) is observed at the same 
time as the signal in the other channel (red). The plugin performs a 
converging search for the image thresholds and reports various met-
rics on the resulting thresholded images. We used the percentage vol-
ume metric. The colocalization colors are: red + green = yellow; red + 
cyan = magenta; and red + green + cyan = white.
TUNEL assay. To evaluate cell death by apoptosis, we used a 
Roche In Situ Cell Death Detection Kit with fluorescein according to 
the manufacturer’s protocol. Briefly, human MDMs were differentiat-
ed on glass slides and treated with IL-26 or overnight. Cells were then 
washed, fixed, and labeled with TUNEL reaction mixture. Nuclei were 
stained with DAPI. Immunofluorescence was assessed using a Leica 
TCS-SP MP inverted single confocal laser-scanning microscope and a 
2-photon laser microscope (Leica) at the Advanced Microscopy/Spec-
troscopy and Macro-Scale Imaging Laboratory (California NanoSys-
tems Institute, UCLA).
Immunoblot analysis. MDMs (2 × 106 cells per condition) were 
collected in NP-40 lysis buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 5 
mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1% NP-40, 0.02% NaN3, and 
1 mM PMSF) containing complete protease inhibitors (Roche Applied 
Science). Total protein from cell lysates was quantified by the Bradford 
assay. Lysates were separated on a 7.5% nondenaturing gel, followed 
by immunoblot analysis with anti-HSP90 and anti-LC3, with detec-
tion by ECL (Pierce Biotechnology, Thermo Fisher Scientific).
Statistics. The statistics reported here cover the entire series of 
experiments and are described as the mean ± SEM. GraphPad Prism 6 
software was used for graphing and statistical analysis. For comparisons 
among 3 or more groups, we used repeated measures 1-way ANOVA with 
Greenhouse-Geisser correction, along with Tukey’s multiple compar-
isons test, with individual variances computed for each comparison. A 
2-tailed Student’s t test was used for all other 2-group analyses. For the 
WT and STING–/– experiments, we used repeated-measures 2-way ANO-
VA, along with Tukey’s multiple comparisons test. For all experiments, a 
P value of less than 0.05 was considered statistically significant.
Study approval. This study was conducted according to the prin-
ciples expressed in the Declaration of Helsinki. All donors provided 
written informed consent for the collection of peripheral blood and 
skin specimens for subsequent scientific analysis. All patients were 
recruited with approval from the IRBs of the USC School of Medicine 
and UCLA and the Institutional Ethics Committee of the Oswaldo 
Cruz Foundation.
Author contributions
RLM, ATD, RMBT and DIW designed the experiments, interpret-
ed the data, and drafted the manuscript. BRB assisted with the 
conceptual framework and writing. ATD performed most of the 
experiments. DIW, KP, and GC performed the autophagy immu-
noblotting experiments. RMBT performed microarray analysis 
and quantified confocal imaging. ENS and MTO provided the 
clinical samples. MG assisted with the conceptual framework and 
writing of the manuscript.
Microscale Protein Labeling Kit (Molecular Probes, Invitrogen, Ther-
mo Fisher Scientific). MDMs were treated with labeled recombi-
nant IL-26 (rIL-26) monomers in RPMI media with 10% FCS for 30 
minutes. As a control, MDMs were treated with the Alexa Fluor 488 
dye media used for the labeling reaction. Treated MDMs were next 
infected with live PKH26-labeled M. leprae overnight. Cells were 
then washed and fixed for 30 minutes with 4% PFA and then washed 
again. Next, cells were permeabilized with 0.25% saponin for 20 min-
utes, blocked with serum for 30 minutes, and stained with primary 
Abs against CD68 (clone Y1/82A, IgG2b, BioLegend), LAMP1 (clone 
H4A3, IgG1, BioLegend), or LC3 (clone 4E12, IgG1, MBL Internation-
al) for 2 hours. Following washing, cells were stained with secondary 
Abs (Molecular Probes, Invitrogen, Thermo Fisher Scientific) for 90 
minutes, washed, and mounted with ProLong Gold with DAPI (Invit-
rogen, Life Technologies, Thermo Fisher Scientific). For the quantifi-
cation of autophagy, the percentages of LC3 punctated cells were eval-
uated using fluorescence microscopy. Approximately 100 cells, over 6 
different random fields of view, were scored for each condition of each 
experiment. Rapamycin was used as a positive control for autophagy 
induction at 300 nM. Immunofluorescence of cell cultures was exam-
ined using a Leica TCS-SP MP inverted single confocal laser-scanning 
microscope and a Leica 2-photon laser microscope at the Advanced 
Microscopy/Spectroscopy Laboratory and Macro-Scale Imaging Lab-
oratory (California NanoSystems Institute, UCLA). Colocalization 
quantifications were performed using ImageJ software (NIH) by split-
ting the final image overlay into individual single channels and select-
ing the “Colocalization Threshold” option to calculate the percentage 
of pixel overlap between channels.
Culture and treatment of WT and STING-KO THP-1 cells. WT and 
STING-KO THP-1 dual reporter cell lines were purchased from Invi-
voGen. The STING-KO THP-1 dual cells were created by stable KO of 
STING in WT THP-1 dual cells. The cells were cultured according to 
the manufacture’s protocol. For all experiments, both WT and STING-
KO THP-1 cells were passaged no more than 5 times. WT and STING-
KO cells were plated at a density of 0.5 × 106 cells/ml on 8-well glass 
slides and were made adherent by treating with 400 ng/ml PMA for 
48 hours. The cells were subsequently treated or not with 2 μM rIL-
26 monomers for 24 hours. Rapamycin (300 nM) was added to some 
wells for 3 hours to serve as a positive control for autophagy induc-
tion. Immunofluorescence labeling for LC3 puncta detection was 
performed as described above in the Cell culture immunofluorescence 
labeling section, with quantification of the number of LC3 puncta per 
cell done using ImageJ software.
Tissue immunofluorescence labeling. Immunofluorescence was per-
formed by serial incubation of cryostat tissue sections with anti-hu-
man mAbs of different isotypes for 2 hours (IL-26, clone 2A8, IgG2a, 
Sigma-Aldrich; CD4, clone A16A1, IgG2b, BioLegend; CD8, clone 
HIT8a, IgG1, BioLegend; CD68, clone KP1, IgG1, Abcam), and then 
washed 3 times with 1× PBS, followed by incubation with isotype-spe-
cific fluorochrome A488-, A568-, and A647-labeled goat anti–mouse 
Ig Abs (Molecular Probes, Invitrogen, Thermo Fisher Scientific) for 90 
minutes. Negative controls were stained with matching isotype Abs. 
Nuclei were stained with DAPI (Invitrogen, Life Technologies, Ther-
mo Fisher Scientific). Immunofluorescence of skin sections was exam-
ined using a Leica TCS-SP MP inverted single confocal laser-scanning 
microscope and a 2-photon laser microscope (Leica) at the Advanced 
Microscopy/Spectroscopy and Macro-Scale Imaging Laboratory (Cal-
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